Application
Western blot analysis of Tafazzin expression in FHs 173We whole cell lysate.WB
A) Immunoblotting for tafazzin from heart tissue of high-fat-diet-fed mice at different time points (4 W, LF n = 5, HF n = 5; 8 W, LF n = 5, HF n = 5; 16 W, LF n = 5, HF n = 5; 24 W, LF n = 5, HF n = 5).C) Immunoblotting for tafazzin from H9c2 cardiomyoblasts treated with 100 µm palmitic acid at different time points.| Product Name | Tafazzin Antibody (H-77) |
|---|---|
| Antibody Type | Primary Antibodies |
| Conjugation | Agarose |
| Modification | Acetylated |
| Modification Notes | Tafazzin protein is a single-pass membrane protein that is abundant in cardiac and skeletal muscle, where it influences mitochondrial structure. There are various isoforms associated with Tafazzin, most of which are ubiquitous. Isoforms with hydrophobic N-terminal domains are membrane anchored, whereas the short isoforms that lack a hydrophobic leader sequence may exist as cytoplasmic proteins. The isoforms that lack the N-terminal domain are not found in cardiac or skeletal muscle, rather they are located in fibro-blasts and leukocytes. Mutations in the Tafazzin gene are associated with various diseases, including dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, left ventricular noncompaction (LVNC) and Barth syndrome (BTHS), a severe inherited disorder marked by neutropenia, cardiac and skeletal myopathy and short stature. |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | ELISAIFIPWB |
| WB:1:100~1:500 IP:1:20~1:100 IF:1:20~1:100 |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml |
| Purification | Affinity purified |
| Alternative Names | epitope corresponding to amino acids 216-292 mapping at the C-terminus of Tafazzin of human origin |
|---|---|
| Tissue Specificity | epitope corresponding to amino acids 216-292 mapping at the C-terminus of Tafazzin of human origin |
| Entrez Gene | 6901 |
|---|
Application
Western blot analysis of Tafazzin expression in FHs 173We whole cell lysate.
WB
A) Immunoblotting for tafazzin from heart tissue of high-fat-diet-fed mice at different time points (4 W, LF n = 5, HF n = 5; 8 W, LF n = 5, HF n = 5; 16 W, LF n = 5, HF n = 5; 24 W, LF n = 5, HF n = 5).C) Immunoblotting for tafazzin from H9c2 cardiomyoblasts treated with 100 µm palmitic acid at different time points.| Application Notes | WB:1:100~1:500 IP:1:20~1:100 IF:1:20~1:100 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
